Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 8.93
Key Takeaways
Risk factor
Negligible price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very strong margins and returns
Data is available to registered users only
Data is available to registered users only
About
Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products for the treatment of diabetes and cardiovascular-based diseases in China. The company operates through Pharmaceutical Industry and Building Materials Industry segments. Its lead product portfolio includes insulin analogues, such as insulin glargine, Insulin aspart, and insulin lispro; antidiabetic drugs; and oral hypoglycemic...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is underpriced on P/E, of fair value
Data is available to registered users only
Buy
Sell